Dr. Sondel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1111 Highland Ave
Madison, WI 53705
Education & Training
- University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1978 - 1980
- University of MinnesotaInternship, Pediatrics, 1977 - 1978
- Harvard Medical SchoolClass of 1977
Certifications & Licensure
- WI State Medical License 1978 - 2025
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Elected Member The American Society for Clinical Investigation, 1988
- Join now to see all
Clinical Trials
- Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Start of enrollment: 2001 Oct 01
- hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Start of enrollment: 2005 Aug 01
- N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 122 citationsA First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsJeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E Kohrt
Clinical Cancer Research. 2017-12-04 - 119 citationsCharacterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain wit...Stephan D. Voss, Paul M. Sondel, R J Robb
The Journal of Experimental Medicine. 1992-08-01 - 82 citationsImmunocytokines for cancer treatment: past, present and futureDario Neri, Paul M. Sondel
Current Opinion in Immunology. 2016-04-06
Press Mentions
- To Save Children with Cancer, Doctors Turn to New WeaponsAugust 5th, 2022
- First-in-Humans Clinical Trial to Treat Children with Relapsed Neuroblastoma Opens at American Family Children’s HospitalNovember 19th, 2020
- New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against ThemselvesOctober 23rd, 2019
- Join now to see all
Grant Support
- The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 ImmunotherapyNational Cancer Institute2012
- Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated MacrophagesNational Cancer Institute2008–2011
- Clinical Development Of Hu14.18-Il2 Targeted TherapyNational Cancer Institute2006–2011
- Phase I Study Of Fenretinide LXS Oral Powder In Patients With NeuroblastomaNational Center For Research Resources2007
- Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced MelanomaNational Center For Research Resources2006–2007
- 131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell RescueNational Center For Research Resources2006–2007
- T-Cell Independent Antitumor Mechanisms Of CD40 LigationNational Cancer Institute2002–2005
- Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ TumorsNational Center For Research Resources2004
- Clinical Development Of Hu14.18 IL2 Targeted TherapyNational Cancer Institute2000–2004
- Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources1999–2002
- Maintenance Treatment Of Therapy Refractory All W/ B43 PAP ImmunotoxiNational Center For Research Resources1999–2002
- Systemic Immunity By Particle Mediated BRM Gene TransferNational Cancer Institute1996–1999
- Clinical Testing Of Ch1418-Il2 For Gd2+ TumorsNational Cancer Institute1996–1998
- Antibody IL-2 Fusion Protein Delivery By Gene TransferNational Cancer Institute1996–1998
- Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With MelanomaNational Center For Research Resources1995–1996
- In Vitro Reactivity And Regulation Of Lymphocyte Response In LymphocytesNational Center For Research Resources1995
- Combined Modality Antibody Directed Cell CytotoxicityNational Cancer Institute1995
- Combined Modality Antibody-Directed Cell CytotoxicityNational Cancer Institute1993–1995
- Antitumor Artificial Receptors As Cancer VaccinesNational Cancer Institute1992–1995
- Immunobiology Of Antileukemic LymphocytesNational Cancer Institute1994
- Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1990–1994
- Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1990–1993
- BRM Monitoring Of Pediatric Neuroblastoma/OsteosarcomaNational Cancer Institute1990–1991
- Autologous LAK Cells &Il-2 In Cancer PatientsDivision Of Cancer Treatment1987–1990
- The Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute1985–1989
- Clinical Trial Of Natural And Recombinent Interleukin-2Division Of Cancer Treatment1986
- Core--Scintillation Counting ServicesNational Cancer Institute1985
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: